← Back to Screener
Nasus Pharma Ltd. (NSRX)
Price$2.93
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-68.38%
Price vs S&P 500 (4W)-6.97%
VGM Score23.26
Market Capitalization$26.31M
All Metrics
Book Value / Share (Quarterly)$0.31
Cash Flow / Share (Quarterly)$-0.55
Price vs S&P 500 (YTD)-75.22%
EPS (TTM)$-0.87
10-Day Avg Trading Volume0.06M
EPS Excl Extra (TTM)$-0.87
EPS (Annual)$-1.46
ROI (Annual)-423.12%
Cash / Share (Quarterly)$0.14
ROA (Last FY)-234.05%
EBITD / Share (TTM)$-0.67
Cash Flow / Share (Annual)$-1.09
P/B Ratio9.51x
P/B Ratio (Quarterly)28.47x
Net Income / Employee (Annual)$-1,673,100
Net Interest Coverage (TTM)-12.28x
ROA (TTM)-251.92%
EPS Incl Extra (Annual)$-1.46
Current Ratio (Annual)2.24x
Quick Ratio (Quarterly)2.01x
3-Month Avg Trading Volume0.15M
Revenue / Employee (TTM)$0
52-Week High$9.99
EPS Excl Extra (Annual)$-1.46
26-Week Price Return-60.46%
Quick Ratio (Annual)2.09x
13-Week Price Return-41.28%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.24x
Enterprise Value$25.08M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.14
3-Month Return Std Dev148.76%
Net Income / Employee (TTM)$-1,015,400
ROE (Last FY)-423.12%
Net Interest Coverage (Annual)-4.83x
EPS Basic Excl Extra (Annual)$-1.46
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.87
Revenue / Share (Annual)$0.00
Year-to-Date Return-67.98%
5-Day Price Return-12.28%
EPS Normalized (Annual)$-1.46
Month-to-Date Return-12.80%
EBITD / Share (Annual)$-1.22
EPS Basic Excl Extra (TTM)$-0.87
P/B Ratio (Annual)28.47x
Book Value / Share (Annual)$0.31
Price vs S&P 500 (13W)-49.54%
Beta1.45x
Revenue / Share (TTM)$0.00
52-Week Low$1.98
mGradeD
vgmGradeD
Show chart for
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.13
4.13
4.13
4.13
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
NSRXNasus Pharma Ltd. | — | — | D | $2.93 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Nasus Pharma is a clinical-stage specialty pharmaceutical company developing intranasal formulations for acute emergencies, including opioid overdose and anaphylactic shock. Its portfolio includes intranasal naloxone, which has completed pivotal clinical trials, and intranasal epinephrine in phase 2 development, supported by proprietary microsphere technology.